Table 2.
S. No. | Vaccines | Types | Carriers | Doses |
---|---|---|---|---|
1 | Oxford-AstraZeneca (ChAdOx1nCoV-19, AZD1222) (University of Oxford, Oxford, UK) |
Viral vector, targeted towards S protein |
Modified Chimpanzee Adenovirus ChAdOx1 | 2 doses 8 to 12 weeks apart, i.m. |
2 | Pfizer-BioNTech (BNT162b2) | Nucleoside modified mRNA |
Lipid nanoparticles | 2 doses 21 to 28 days apart, i.m. |
3 | Johnson and Johnson (Ad26.COV2.S, Janssen) | S protein of SARS-CoV-2 WA1/2020 strain | Recombinant, replication incompetent adenovirus Ad26 | Single dose, i.m. |
4 | Moderna (mRNA-1273) | Nucleoside modified mRNA |
Lipid nanoparticles | 2 doses, 4 to 6 weeks apart, i.m. |
5 | Sinopharm (BBIBP-CorV) | Inactivated virus (2019-CoV) | Inactivated virus + adjuvant |
2 doses, 3–4 weeks apart, i.m. |
6 | CoronaVac (Sinovac) | Inactivated virus | Inactivated virus + adjuvant |
2 doses, 2–4 weeks apart, i.m. |
i.m., intramuscular.